BioSpace News Archive

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2022, and provided clinical development and operational highlights.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2022, ended June 30, 2022.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for its first quarter of fiscal year 2023 ended June 30, 2022 and provided a corporate update.

Athersys, Inc. announced its financial results for the three and six months ended June 30, 2022 and provided a business update.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced the commencement of a proposed public offering of 1,000,000 shares of its common stock.

Travere Therapeutics, Inc. announced that on August 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants to 29 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 101,500 shares of its common stock.

Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials.

Agile Therapeutics, Inc., a women’s healthcare company, reported financial results for the three months ended June 30, 2022 and provided a corporate update.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, provided a business update and reported financial results for the second quarter June 30, 2022.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the second quarter of 2022.